Mizuho raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $23 from $20 and keeps a Neutral rating on the shares. The District Court of Delaware ruled in Acadia’s favor on the patent infringement case against Aurobindo Pharma, the analyst tells investors in a research note. The firm cites the favorable district court ruling for the target raise but still has concerns about Daybue adoption.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- Acadia Pharmaceuticals price target raised to $31 from $28 at Baird
- ACADIA Pharmaceuticals’ Legal Victory and Pipeline Expansion Drive Buy Rating and Increased Price Target
- Acadia Pharmaceuticals price target raised to $32 from $27 at H.C. Wainwright
- Acadia court ruling alleviates overhang for Nuplazid, says RBC Capital
- Acadia confirms court ruling in favor of Nuplazid formulation patent